Interleukin-1 receptor antagonist gene polymorphism in patients with rheumatoid arthritis in India

Indian Journal of Medical Research

Volumn 123, Issue 6, 2006, Pages 815-820

  Grover, S ^a   Tandon, S ^a   Misra, R ^a   Aggarwal, Amita ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytokine antagonist; Interleukin 1 receptor; Rheumatoid arthritis; Sj gren's syndrome

Indexed keywords

DNA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CALCULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SAMPLE SIZE; SJOEGREN SYNDROME; SUBCUTANEOUS NODULE;

ARTHRITIS, RHEUMATOID; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; POLYMORPHISM, GENETIC;

EID: 33747640558     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lawrence JS. Prevalence of rheumatoid arthritis. Ann Rheum Dis 1961; 20: 11-7.
2. Malaviya AN, Kapoor S, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 1993; 13: 131-4.
3. Wagner U, Kaltenhauser S, Sauer H, Arnold S, Seidel W, Hantzschel H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997; 40: 341-51.
4. Van zehen D, Hazes JM, Zwinderman AH, Cats A, Schreuder GM, D'Amaro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis: results of a follow up study. Arthritis Rheum 1991; 34: 822-30.
5. Deighton CM, Walker DJ, Griffiths ID, Roberts DF. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989; 36: 178-82.
6. Arend WP, Gabay C. Physiologic role of interleukin-1 receptor antagonist. Arthritis Res 2000; 2: 245-8.
7. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembeling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-20.
8. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164-72.
9. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-09.
10. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable number of 86-bp tandem repeats. Hum Genet 1993; 91: 403-4.
11. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1380-5.
12. Perrier S, Coussediere C, Dubost JJ, Albuisson E, Sauvezie B. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 1998; 87: 309-13.
13. Vencovsky J, Jarsova K, Ruzickova S, Nemcova D, Niderlova J, Ozen S, et al. Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. Arthritis Rheum 2001; 44: 2387-91.
14. van der Paardt M, Crusius JBA, Garcia-Gonzalez MA, Baudoin P, Kostense PJ, Alizadeh BZ, et al. Interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphism in ankylosing spondylitis. Rheumatology (Oxford) 2002; 41: 1419-23.
15. Vijgen L, Van gysel M, Rector A, Thoelen I, esters N, Ceelen T, et al. Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes Immun 2002; 3: 400-6.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 1988; 16: 1215-8.
18. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1a, interleukin-1b and interleukin-1 receptor antagonist genes. Genomics 1994; 19: 382-4.
19. Lee YH, Kim HJ, Rho YH, Choi SJ, Ji JD, Song GG. Interleukin-1 receptor antagonist gene polymorphism and rheumatoid arthritis. Rheumatol Int 2004; 24: 133-6.
20. Huang CM, Tsai FJ, Wu JY, Wu MC. Interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphism in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 225-8.
21. Cantagrel A, Navaux F, Loubet-Lescoulie P, Nourhashemi F, Enault G, Abbal M, et al. Interleukin-1 beta, interleukin-1 receptor antagonist, interleukin-4 and interleukin-10 gene polymorphism: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42: 1093-100.
22. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S, Lefvert AK. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1 beta and IL-1Ra genes. J Rheumatol 2002; 29: 212-9.
23. Hurme M, Santilla S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-602.
24. Kaijzel EL, van Dongen H, Bakkar AM, Breedveld FC, Huiziniga TWJ, Verweij CL. Relationship of polymorphisms of the interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis. Tissue Antigens 2002; 59: 122-6.